Covered recipient · General Payments record
NADEGE T GUNN
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2025 · Entire year
$487,497.14
353 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2025 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $220,684.38 | 55 |
| Consulting Fee | $180,868.75 | 30 |
| Travel and Lodging | $76,966.94 | 125 |
| Food and Beverage | $8,944.80 | 142 |
| Education | $32.27 | 1 |
By paying entity
PY2025 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Madrigal Pharmaceuticals | $164,703.61 | 140 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $126,101.21 | 90 |
| Novo Nordisk Inc | $64,448.55 | 31 |
| Boehringer Ingelheim International GmbH | $46,110.71 | 21 |
| Gilead Sciences, Inc. | $43,210.86 | 36 |
| Ipsen Biopharmaceuticals, Inc | $37,885.01 | 20 |
| Intercept Pharmaceuticals, Inc. | $2,900.00 | 1 |
| F. Hoffmann-La Roche AG | $1,454.97 | 4 |
| GlaxoSmithKline, LLC. | $400.00 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $146.47 | 4 |
| ABBVIE INC. | $54.55 | 3 |
| Mirum Pharmaceuticals, Inc. | $52.48 | 1 |
| Genentech, Inc. | $28.72 | 1 |
Page 4 of 8; records 151–200 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NADEGE T GUNN
NPI 1902822281 · CMS profile ID 267222
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
WACO, TX
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 4 of 8; records 151–200 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=4#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NADEGE T GUNN, NPI 1902822281, CMS profile ID 267222. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- APA 7
- IndustryPayments. (2026). NADEGE T GUNN, NPI 1902822281, CMS profile ID 267222. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 8; records 151–200 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
- Bluebook
- NADEGE T GUNN, NPI 1902822281, CMS profile ID 267222, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 8; records 151–200 of 353 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1902822281?year=2025&recipient=provider&page=4#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30
353 matching records · $487,497.14 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 151–200 of 353.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | $1,763.00 | 08/07/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266074 | CMS |
| Novo Nordisk Inc | $83.48 | 08/06/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188419304 | CMS |
| Madrigal Pharmaceuticals | $36.68 | 07/30/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266070 | CMS |
| Madrigal Pharmaceuticals | $2,468.00 | 07/30/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266072 | CMS |
| Madrigal Pharmaceuticals | $143.37 | 07/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266058 | CMS |
| Madrigal Pharmaceuticals | $21.38 | 07/29/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266060 | CMS |
| Madrigal Pharmaceuticals | $5,993.00 | 07/29/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266062 | CMS |
| Madrigal Pharmaceuticals | $323.13 | 07/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266064 | CMS |
| Madrigal Pharmaceuticals | $452.00 | 07/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266066 | CMS |
| Madrigal Pharmaceuticals | $925.96 | 07/29/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266068 | CMS |
| Novo Nordisk Inc | $10.12 | 07/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188318877 | CMS |
| Novo Nordisk Inc | $16.25 | 07/22/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1189096187 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $8,085.00 | 07/21/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985367 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.00 | 07/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985371 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $140.00 | 07/21/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985393 | CMS |
| Madrigal Pharmaceuticals | $38.03 | 07/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266050 | CMS |
| Madrigal Pharmaceuticals | $94.65 | 07/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266052 | CMS |
| Madrigal Pharmaceuticals | $57.41 | 07/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266054 | CMS |
| Madrigal Pharmaceuticals | $70.44 | 07/19/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266056 | CMS |
| ABBVIE INC. | $19.07 | 07/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1201978053 | CMS |
| Madrigal Pharmaceuticals | $688.57 | 07/18/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266040 | CMS |
| Madrigal Pharmaceuticals | $244.08 | 07/18/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266042 | CMS |
| Madrigal Pharmaceuticals | $5,287.50 | 07/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266044 | CMS |
| Madrigal Pharmaceuticals | $231.58 | 07/18/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266046 | CMS |
| Madrigal Pharmaceuticals | $196.14 | 07/18/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266048 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $35.00 | 07/09/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985373 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13,230.00 | 07/09/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985375 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $140.00 | 07/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985377 | CMS |
| Madrigal Pharmaceuticals | $1,763.00 | 06/26/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266038 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $47.62 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985329 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $47.62 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985331 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $38.19 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985333 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.28 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985335 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $143.62 | 06/25/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985337 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $53.30 | 06/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985339 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $213.43 | 06/25/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985343 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $386.61 | 06/24/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985341 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $147.77 | 06/21/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985307 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $26.90 | 06/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985365 | CMS |
| Genentech, Inc. | $28.72 | 06/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1211556738 | CMS |
| Madrigal Pharmaceuticals | $5.55 | 06/21/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266036 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $168.17 | 06/20/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985305 | CMS |
| Madrigal Pharmaceuticals | $1,763.00 | 06/18/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266034 | CMS |
| Madrigal Pharmaceuticals | $1,763.00 | 06/17/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1248266032 | CMS |
| Novo Nordisk Inc | $3,140.00 | 06/14/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1188453155 | CMS |
| Boehringer Ingelheim International GmbH | $5,145.00 | 06/11/2025 | Consulting Fee | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1215872976 | CMS |
| Ipsen Biopharmaceuticals, Inc | $5,096.00 | 06/11/2025 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208843427 | CMS |
| Ipsen Biopharmaceuticals, Inc | $1,833.50 | 06/11/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208843429 | CMS |
| Ipsen Biopharmaceuticals, Inc | $124.98 | 06/11/2025 | Food and Beverage | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1208843431 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $100.44 | 06/09/2025 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1222985359 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Principal investigator | $1,235,295.76 | 387 |
| PY2024 | Recipient | $19.05 | 1 |
| PY2024 | Principal investigator | $864,482.52 | 85 |
| PY2023 | Recipient | $1,761.83 | 2 |
| PY2023 | Principal investigator | $570,518.92 | 29 |
| PY2022 | Recipient | $577.01 | 3 |
| PY2022 | Principal investigator | $158,872.78 | 17 |
| PY2021 | Recipient | $2,757.60 | 1 |
| PY2021 | Principal investigator | $190,613.34 | 24 |
| PY2020 | Principal investigator | $531,012.75 | 21 |
| PY2019 | Recipient | $144.86 | 2 |
| PY2019 | Principal investigator | $1,223,702.45 | 69 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
387 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 12/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729307 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 12/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729309 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $163.24 | 12/17/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728983 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 12/17/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728985 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $693.50 | 12/17/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728987 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 12/17/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728989 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $59.94 | 12/17/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 12/10/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 12/10/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728973 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,612.00 | 12/08/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808244 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $400.00 | 12/02/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220800860 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728825 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728827 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728829 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728831 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728833 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728835 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729295 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 12/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729297 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 12/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770557 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 11/27/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728911 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,143.38 | 11/27/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728913 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,913.44 | 11/27/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728915 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,511.73 | 11/27/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728917 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 11/27/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728919 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 11/27/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728969 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,608.00 | 11/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729281 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,608.00 | 11/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729283 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,608.00 | 11/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729285 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,796.00 | 11/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729287 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,018.00 | 11/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729289 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,986.00 | 11/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729291 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,986.00 | 11/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729293 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $99.90 | 11/19/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728925 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $255.50 | 11/19/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728927 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.20 | 11/19/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728929 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 11/19/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728931 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 11/19/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728979 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 11/19/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728981 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $8,073.00 | 11/13/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808242 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $269.00 | 11/07/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808240 |
| Principal investigator 1 | Genentech, Inc. | $14,500.00 | 11/07/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with T2DM | No dispute reported | 06/30/2026 | 1211682274 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728813 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728815 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728817 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728819 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728821 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729277 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 11/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729279 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 11/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770555 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 10/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729299 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 10/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729301 |
| Principal investigator 1 | Genentech, Inc. | $63,662.00 | 10/29/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211682252 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 10/28/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729303 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 10/28/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729305 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 10/27/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728837 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.74 | 10/27/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728839 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $79.92 | 10/27/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728921 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $401.50 | 10/27/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728923 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,250.41 | 10/27/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728967 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 10/27/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728975 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 10/27/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728977 |
| Principal investigator 1 | Genentech, Inc. | $2,751.00 | 10/23/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211682242 |
| Principal investigator 1 | Genentech, Inc. | $13,558.00 | 10/09/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | Effect of RO7204239 in combination with tirzepatide in participants with overweight or obesity | No dispute reported | 06/30/2026 | 1211682240 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,016.00 | 10/02/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729271 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $11,200.00 | 10/02/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729273 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $20,150.00 | 10/02/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729275 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728801 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728803 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728805 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728807 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728809 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728811 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729267 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 10/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729269 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 10/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770549 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $129.00 | 10/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770551 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 10/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770553 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 09/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729247 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 09/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729249 |
| Principal investigator 1 | Bausch Health US, LLC | $3,524.92 | 09/24/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841876 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 09/24/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728797 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.18 | 09/24/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728799 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,267.30 | 09/18/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808238 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $382.00 | 09/17/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729233 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 09/17/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729235 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $418.00 | 09/17/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729237 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 09/17/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729239 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.00 | 09/17/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729245 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $687.00 | 09/17/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729255 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,644.52 | 09/12/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248250021 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $18,500.00 | 09/11/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220800858 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728765 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728767 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728769 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728771 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728773 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728791 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729209 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 09/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729211 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 09/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770547 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 08/29/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729241 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 08/29/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729243 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,500.02 | 08/28/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728873 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 08/28/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728885 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $22,109.34 | 08/28/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728889 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.96 | 08/26/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728965 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $438.00 | 08/26/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729259 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $366.42 | 08/26/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729261 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $9.72 | 08/26/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729263 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.04 | 08/26/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729265 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $229.00 | 08/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729217 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $313.00 | 08/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729227 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $100.00 | 08/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729229 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,897.40 | 08/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248248971 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $417.00 | 08/18/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729219 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $418.00 | 08/18/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729221 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.00 | 08/18/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729223 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.00 | 08/18/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729225 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $229.00 | 08/18/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729231 |
| Principal investigator 1 | Bausch Health US, LLC | $9,134.12 | 08/08/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841872 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $30,769.20 | 08/06/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808236 |
| Principal investigator 1 | Boehringer Ingelheim Pharma GmbH & Co.KG | $6,676.96 | 08/05/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220998435 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728755 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728757 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728759 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728761 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728763 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $30.79 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728785 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728789 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.65 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728875 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $375.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728877 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $400.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728879 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.16 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $806.20 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728883 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $500.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728887 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.65 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728891 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $243.25 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728893 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $125.10 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728895 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $278.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728897 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729205 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 08/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729207 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 08/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770545 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 07/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729251 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 07/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729253 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $770.06 | 07/30/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728961 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $219.00 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728793 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.22 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728795 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $174.90 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728905 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728907 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.85 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728909 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728963 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $182.50 | 07/28/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729257 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,986.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729181 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,226.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729185 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,386.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729191 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,386.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729193 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $135.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729197 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $135.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729199 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $107.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729201 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $44.00 | 07/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729203 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $391.52 | 07/25/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220815069 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,025.00 | 07/09/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808234 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,226.00 | 07/07/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729183 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,018.00 | 07/07/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729187 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,018.00 | 07/07/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729189 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,118.00 | 07/07/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729195 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,252.88 | 07/04/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248246583 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728775 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728777 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728779 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728781 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728783 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728787 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728871 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729213 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 07/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729215 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 07/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770543 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 06/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729171 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 06/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729173 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $125.10 | 06/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728943 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $278.00 | 06/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728945 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $90.35 | 06/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728947 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $48.65 | 06/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728949 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $243.25 | 06/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728951 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $125.00 | 06/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728953 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $152.90 | 06/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728955 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 06/24/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728751 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3.48 | 06/24/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728753 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 06/24/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728957 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $36.50 | 06/24/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728959 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $73.00 | 06/24/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729177 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1.08 | 06/24/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729179 |
| Principal investigator 1 | Bausch Health US, LLC | $2,428.16 | 06/05/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841899 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $20,544.30 | 06/05/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808232 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $300.00 | 06/05/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547131 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,150.00 | 06/05/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728735 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728737 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728739 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728741 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728743 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728745 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728901 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729159 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 06/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729161 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.75 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770535 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $24.94 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770537 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $86.00 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770539 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 06/01/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with type 2 diabetes, hypertension and established cardiovascular disease. | No dispute reported | 06/30/2026 | 1220770541 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 05/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729167 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 05/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729169 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,250.00 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547121 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $13,000.00 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547123 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $1,300.00 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547125 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,032.00 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547127 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $2,500.00 | 05/28/2025 | Non-covered Recipient Entity Velocity Clinical Research | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176547129 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,252.88 | 05/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244674 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,259.00 | 05/27/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729151 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.30 | 05/27/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729175 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $4,445.00 | 05/27/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800678 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 05/26/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192098710 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,644.52 | 05/15/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243853 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $695.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729135 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $85.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729137 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $626.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729139 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $764.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729141 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $518.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729143 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $800.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729145 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,045.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729147 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $245.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729149 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,748.00 | 05/09/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729153 |
| Principal investigator 1 | Bausch Health US, LLC | $3,242.26 | 05/07/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841894 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728723 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728725 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728727 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728729 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728731 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728733 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729155 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 05/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729157 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 04/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729163 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 04/30/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729165 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $14,190.12 | 04/28/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242823 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,217.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729099 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729101 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $61.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729103 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,118.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729105 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729107 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $135.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729109 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $135.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729111 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $40.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729113 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729115 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,774.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729117 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,226.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729119 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,118.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729121 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,386.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729123 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,118.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729125 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,986.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729127 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $452.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729129 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $44.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729131 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $107.00 | 04/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729133 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $657.00 | 04/23/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728747 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.44 | 04/23/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728749 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,259.00 | 04/11/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729089 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,774.00 | 04/11/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729091 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $16,259.00 | 04/11/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729093 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,774.00 | 04/11/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729095 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 04/11/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729097 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,491.80 | 04/11/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808230 |
| Principal investigator 1 | Bausch Health US, LLC | $13,024.40 | 04/01/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841903 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728711 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728713 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728715 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728717 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728719 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728721 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728865 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 04/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 03/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 03/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 03/25/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728861 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $146.00 | 03/25/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728863 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $365.00 | 03/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $305.35 | 03/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729079 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $8.10 | 03/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.20 | 03/25/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729083 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,066.70 | 03/24/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808228 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,120.00 | 03/12/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800676 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000.00 | 03/12/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808226 |
| Principal investigator 1 | Bausch Health US, LLC | $2,428.16 | 03/11/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841885 |
| Principal investigator 1 | Eli Lilly and Company | $1,254.00 | 03/06/2025 | Non-covered Recipient Entity AUSTIN GASTROENTEROLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187877767 |
| Principal investigator 2 | Madrigal Pharmaceuticals | $5,343.17 | 03/06/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240392 |
| Principal investigator 1 | Bausch Health US, LLC | $3,111.50 | 03/05/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841888 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,774.00 | 03/03/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 03/03/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,226.00 | 03/03/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728691 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728693 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728695 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728697 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728699 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $49.88 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728701 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $43.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728703 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728705 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728867 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 03/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 02/28/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 02/28/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729057 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $8,000.00 | 02/27/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $109.50 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728707 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $19.98 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728855 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,058.50 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728857 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $10.00 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728859 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $209.88 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728933 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728935 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $730.00 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728937 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $58.62 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728939 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $6.00 | 02/25/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/metabolic dysfunction associated steatohepatitis (NASH/MASH) cirrhosis | No dispute reported | 06/30/2026 | 1220728941 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,000.00 | 02/21/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH INC | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192098704 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5,000.00 | 02/13/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728849 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,500.00 | 02/13/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728851 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $14,500.00 | 02/13/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728853 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $4,775.22 | 02/06/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239216 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728679 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728681 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728685 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728687 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728689 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728899 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 02/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729045 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $5,000.00 | 02/01/2025 | Non-covered Recipient Entity Velocity Clinical Research Durham | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220800674 |
| Principal investigator 1 | Bausch Health US, LLC | $709.10 | 01/31/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841881 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $35.00 | 01/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $42.00 | 01/31/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729053 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 01/27/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $292.00 | 01/27/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729071 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.16 | 01/27/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729073 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $23.36 | 01/27/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729075 |
| Principal investigator 1 | Boehringer Ingelheim Pharmaceuticals, Inc. | $17,775.00 | 01/17/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220808224 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $93,347.05 | 01/17/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH WACO | A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214124592 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4,217.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220728991 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $902.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220728993 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,451.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220728995 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,001.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220728997 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $979.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220728999 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,954.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729001 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,226.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729003 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729005 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729007 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,451.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729009 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,001.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729011 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,954.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729013 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,226.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729015 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729017 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,451.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729019 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,001.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729021 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,954.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729023 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,226.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729025 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729027 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,641.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729029 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,451.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729031 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $979.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729033 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $3,001.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729035 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2,954.00 | 01/15/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729037 |
| Principal investigator 1 | Bausch Health US, LLC | $2,428.16 | 01/07/2025 | Non-covered Recipient Entity IMPACT RESEARCH INSTITUTE 54723 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis | No dispute reported | 06/30/2026 | 1224841891 |
| Principal investigator 1 | Eli Lilly and Company | $60,652.00 | 01/07/2025 | Non-covered Recipient Entity AUSTIN GASTROENTEROLOGY | A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF TIRZEPATIDE ON THE REDUCTION OF MORBIDITY AND MORTALITY IN ADULTS WITH OBESITY | No dispute reported | 06/30/2026 | 1187880869 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728669 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728671 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728673 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728675 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728677 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $47.50 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A Phase 3, randomised, double-blind, parallel-group, event-driven, cardiovascular safety study with BI 456906 administered subcutaneously compared with placebo in participants with overweight or obesity with established cardiovascular disease (CVD) or chronic kidney disease, and/or at least two weight-related complications or risk factors for CVD | No dispute reported | 06/30/2026 | 1220728709 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728841 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728843 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728845 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220728847 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.00 | 01/01/2025 | Non-covered Recipient Entity Impact Research Institute | Multicenter, randomised, double-blind, placebo-controlled, 48 week, Phase III trial to evaluate the efficacy and safety of survodutide administered subcutaneously in participants with overweight or obesity and presumed or confirmed non-alcoholic steatohepatitis (NASH) | No dispute reported | 06/30/2026 | 1220729041 |
| Principal investigator 1 | VERTEX PHARMACEUTICALS INCORPORATED | $327,327.38 | 01/01/2025 | Non-covered Recipient Entity VELOCITY CLINICAL RESEARCH WACO | A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy | No dispute reported | 06/30/2026 | 1214124304 |